Relieves inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ANDA 209828, held by Macleods Pharms. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 209828 (Triamcinolone Acetonide), held by Macleods Pharms, was first approved by FDA on Nov 23, 2018, with 0 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Triamcinolone Acetonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2018 | Original application | Approved | None posted |
| Triamcinolone Acetonide0.025% · ointment;topical | Triamcinolone Acetonide | Rx |
| Triamcinolone Acetonide0.1% · ointment;topical | Triamcinolone Acetonide | Rx |
| Triamcinolone Acetonide0.5% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
